Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
LKB1 CRISPR/Cas9 KO Plasmid (h): sc-400313
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LKB1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the LKB1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: LKB1 Antibody (Ley 37D/G6): sc-32245
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LKB1 CRISPR/Cas9 KO Plasmid (h) | sc-400313 | 20 µg | $397.00 |
Overview
STK11 encodes the serine/threonine kinase LKB1, a master regulator of cellular energy homeostasis and polarity through phosphorylation of AMPK and related AMPK-family kinases. By integrating nutrient and stress cues, LKB1 influences mTOR signaling, autophagy, mitochondrial metabolism, and cell-cycle control, and it contributes to epithelial organization via polarity complexes. Disruption of LKB1-dependent signaling is linked to altered metabolic adaptation, impaired polarity, and genomic stress responses. STK11 is frequently studied in cancer biology and hereditary tumor predisposition contexts, where loss of LKB1 function reshapes growth control and metabolic pathways.
LKB1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the STK11 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the STK11 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the STK11 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish LKB1 protein expression.
This CRISPR knockout system enables efficient generation of STK11-deficient cell models for investigation of LKB1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting STK11 exon(s) critical for LKB1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple STK11 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by LKB1 CRISPR/Cas9 KO Plasmid (h) and LKB1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the STK11 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by LKB1 HDR Plasmid (h) and LKB1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by STK11 homology arms to support homology-directed repair at defined STK11 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.